|
2016年4月21日，《美国医学会杂志·肿瘤学分册》（JAMA Oncology）在线发表了加利福尼亚大学洛杉矶分校（UCLA）的前瞻性纵向研究二次分析，发现蒽环类与非蒽环类化疗后神经认知功能无显著差异。 JAMA Oncol. 2016 Apr 21. [Epub ahead of print] Comparison of Neurocognitive Function After Anthracycline-Based Chemotherapy vs Nonanthracycline-Based Chemotherapy. Kathleen Van Dyk; Laura Petersen; Patricia A. Ganz.
This secondary analysis of a prospective longitudinal study investigates whether anthracycline chemotherapy confers greater risk of cognitive decline for breast cancer survivors compared with nonanthracycline-based chemotherapy. As a whole, the possible adverse effects of breast cancer and its treatment on cognitive function are now widely acknowledged, but the risks of specific chemotherapies are still undetermined. A recent retrospective cross-sectional study found lower memory scores on average 2 years after treatment among breast cancer survivors who underwent anthracycline treatment vs those who underwent other chemotherapies or no chemotherapy, accompanied by lower functional connectivity in default mode network regions. However, in an earlier report examining a large sample of patients with breast cancer immediately after primary treatment and adjuvant chemotherapy (the Mind Body Study [MBS]), we found no association between anthracycline exposure and cognitive complaints. To determine risk of lasting cognitive decline with anthracycline treatment, we performed a secondary analysis of cognitive function across multiple domains from the MBS prospective longitudinal study of breast cancer survivors, with evaluations at up to 4 time points. DOI: 10.1001/jamaoncol.2016.0350 |
|
|
